Back to Agenda
Session 6: Joint Clinical Assessment (REA)
Session Chair(s)
Claudine Sapède, PHARMD
Director, Global HTA Policy, NOVARTIS INTERNATIONAL, Switzerland
In this session panellists will discuss the state of play, experience from REA pilots and potential development post 2020 surrounding joint clinical assessments (JCAs) - a key component of the joint work across European HTA agencies. What good quality means for stakeholders in relation to clinical HTA methodological standards for JCAs? What practical as well as policy implications this may have for stakeholders and sustainability of EU cooperation? During the workshop session the audience will also be invited to share its perspective and experience.
Speaker(s)
Anja Schiel, PHD
Special Advisor, Lead Methodologist/Statistician; NOMA, Norwegian Medical Products Agency (NOMA), Norway
Panel Discussion
Edith Frénoy, MA, MSC
Director, European Public Policy – Strategic EU Advocacy Lead, MSD Europe Inc., Belgium
Panel Discussion
Michael Berntgen, PHD
Head of Scientific Evidence Generation, European Medicines Agency, Netherlands
Panel Discussion
Anne Willemsen, MSC
Senior Project Manager, Joint Production Co-Lead Partner - Pharmaceuticals, ZIN - National Health Care Institute, Netherlands
Panel Discussion
Kalitsa Filioussi
European Market Access Director, Hematology, ORE, Novartis Oncology, Italy
Have an account?